ABSTRACT Seven members of a family affected by hereditary antithrombin III deficiency were identified. The disorder was associated with recurrent spontaneous episodes of phlebitis, deep venous thrombosis, and pulmonary embolism in middle age. Danazol, a 17-alkyl derivative of ethinyl testosterone, which has been used to treat other antiprotease deficiency states, was assessed in the management of two men with antithrombin deficiency. In a dose of 600 mg a day danazol appeared to correct the antithrombin deficiency. This drug may provide a useful adjunct to anticoagulant treatment, particularly before surgery.
Inherited antithrombin III deficiency (hereditary thrombophilia) is a rare disorder, first described by Egeberg in 1965,' which is characterised by recurrent, sometimes fatal, deep vein thrombosis and pulmonary embolism. When recognised, the condition is usually treated by long term anticoagulation. The control mechanisms that inhibit blood coagulation are vital for homeostasis. The activation sequence in the coagulation cascade contains negative feedback effects that tend to limit thrombin formation.
Antithrombin is one of the protease inhibitors present in blood and its main role is to inactivate thrombin. Antithrombin also inactivates all the clotting enzymes except factor Vlla. Heparin accelerates the reaction between antithrombin and the clotting enzymes.
The structure of antithrombin has recently been determined and is very similar to that of a, antitrypsin.2 They are believed to have evolved from a common ancestral protein-a mutation resulting in the substitution of a single amino acid (arginine for methionine) in the a, antitrypsin molecule converts this from an inhibitor of elastase to an inhibitor of thrombin.3 Molecular heterogeneity occurs in inherited antithrombin III 
